5th INTERNATIONAL CONFERENCE
NEW CONCEPTS IN LYMPHOID MALIGNANCIES

Estoril, Portugal
October 3-5, 2019

Chairs : Michael Hallek, Georg Lenz, Franck Morschhauser, Laurie Sehn, Louis Staudt
Stephan Stilgenbauer, Andrei Thomas-Tikhonenko

Thursday, October 3, 2019

08:00-08:05	**Welcome**	Michael Hallek (Cologne)

SESSION I - Molecular mechanisms of B-cell neoplasms (B-cell signaling) #1
Chairs: Riccardo Dalla-Favera (New York), Ari Melnick (New York)

08:05-08:25	Mechanisms of B-cell development with relevance to lymphomagenesis	Ulf Klein (Leeds)
08:25-08:30	*Discussion*	
08:30-08:50	Genetics and pathogenesis of aggressive B-cell lymphoma	Riccardo Dalla-Favera (New York)
08:50-08:55	*Discussion*	
08:55-09:15	Signaling components in lymphoma	Thomas Oellerich (Frankfurt)
09:15-09:20	*Discussion*	
09:20-09:40	Pathogenesis of Hodgkin lymphoma	Christian Steidl (Vancouver)
09:40-09:45	*Discussion*	
09:45-10:05	Epigenetics in lymphoma	Ari Melnick (New York)
10:05-10:10	*Discussion*	

SHORT COMMUNICATION:

10:10-10:17	*Resistance to BCR loss in high-grade B-cell non-hodgkin lymphomas*	*Stefano Casola (Milan)*
10:17-10:20	*Discussion*	
10:20-10:40	*Round table discussion*	
10:40-11:05	***Coffee break***	

SESSION II - Molecular mechanisms and clonal evolution of B-cell neoplasms (B-cell signaling) #2
Chairs: Jude Fitzgibbon (London), Christian Reinhardt (Cologne)

11:05-11:25	Evolution of the genomic landscape in CLL	Dan Landau (New-York)
11:25-11:30	*Discussion*	
11:30-11:50	Transformation and genomics in follicular lymphoma	Jude Fitzgibbon (London)
11:50-11:55	*Discussion*	
11:55-12:15	Novel mouse models of aggressive lymphoma reveal distinct molecular vulnerabilities	Christian Reinhardt (Cologne)
12:15-12:20	*Discussion*	

SHORT COMMUNICATIONS:

12:20-12:27	*Genetic modification of primary human B-cells models high-grade lymphoma*	*Rebecca Caeser (Cambridge)*
12:27-12:30	*Discussion*	
12:30-12:37	*Novel coding and regulatory drivers of MCL identified by exome and whole genome sequencing*	*Ryan Morin (Vancouver)*
12:37-12:40	*Discussion*	
12:40-13:00	*Round table discussion*	
13:00-14:30	***Lunch***	

13:20-14:20 **SATELLITE SYMPOSIUM:**
Title: Pushing back the limits : Immunological approaches for the treatment of B-cell lymphomas
Chair: Anas Younes
Speakers: Christian Buske and Jeremy S. Abramson

This symposium is organised by Celgene

SESSION III - Molecular mechanisms of B-cell neoplasms :
Insights from single cell or proteome analysis in lymphoma #3
Chairs: Ash A. Alizadeh (Stanford), Elias Campo (Barcelona)

14:30-14:50	Molecular heterogeneity in mantle cell lymphoma	Elias Campo (Barcelona)
14:50-14:55	*Discussion*	
14:55-15:15	Single cell imaging	Andrea Radtke (Bethesda)
15:15-15:20	*Discussion*	
15:20-15:40	Circulating tumour DNA	Ash A. Alizadeh (Stanford)
15:40-15:45	*Discussion*	

SHORT COMMUNICATIONS:

15:45-15:52	*Role of DDX3X RNA helicase in the development of germinal center derived B-Cell malignancies*	*Marion Lacroix (Montreal)*
15:52-15:55	*Discussion*	
15:55-16:02	*Myc enhancer nucleosome eviction drives T-cell acute lymphoblastic leukemia*	*Laura Belver (New York)*
16:02-16:05	*Discussion*	
16:05-16:35	*Round table discussion*	
16:35-17:00	***Coffee break***	

SESSION IV - Targeting the tumour microenvironment in lymphoma : Mechanisms and therapeutic use
Chairs : Markus Müschen (Los Angeles), Margaret Shipp (Boston)

17:00-17:20	The role of the microenvironment in lymphoma	Karin Tarte (Rennes)
17:20-17:25	*Discussion*	
17:25-17:45	Checkpoint inhibition in lymphoid malignancies	Margaret Shipp (Boston)
17:45-17:50	*Discussion*	
17:50-18:10	Modulation of the tumour microenvironment in CLL	Silvia Deaglio (Turin)
18:10-18:15	*Discussion*	
18:15-18:35	Targeting of kinases to modify the lymphoma microenvironment	Phuong-Hien Nguyen (Cologne)
18:35-18:40	*Discussion*	
18:40-19:00	Metabolic gatekeepers in B-lymphoid malignancies	Markus Müschen (Los Angeles)
19:00-19:05	*Discussion*	

SHORT COMMUNICATION:

19:05-19:12	*Loss of NLRC5 downregulates MHC-1 antigen presentation and leads to immune evasion in follicular lymphoma*	*Jay Gunawardana (Brisbane)*
19:12-19:15	*Discussion*	
19:15-19:35	*Round table discussion*	
19:35	***Free evening***	

Friday, October 4, 2019

08:00-09:00 **SATELLITE SYMPOSIUM:**
Title: Translating scientific advances into improved clinical outcomes in B-cell lymphomas
Chair: Stephan Stilgenbauer
Speakers: Christian Buske, Peter Hillmen and Kostas Stamatopoulos

This symposium is organised by Janssen

08:00-09:00 3 Simultaneous Meet the Expert Sessions (non-clinical)

1. CAR-T — Hinrich Abken (Regensburg) & David Maloney (Seattle)
2. Microenvironment — Silvia Deaglio (Turin)
3. Genomics, pathology and pathogenesis — Ash A. Alizadeh (Stanford)

09:00-09:25 ***Coffee break***

SESSION V - Cellular immunotherapies for lymphoid malignancies
Chairs: David Maloney (Seattle), Andrei Thomas-Tikhonenko (Philadelphia)

09:25-09:45	CARs, TRUCKs and beyond : novel strategies and constructs	Hinrich Abken (Regensburg)
09:45-09:50	*Discussion*	
09:50-10:10	CAR-T cell update in DLBCL	Stephen J. Schuster (Philadelphia)
10:10-10:15	*Discussion*	
10:15-10:35	Longterm follow-up of CD19 CAR therapy in acute lymphoblastic leukaemia	Jae H. Park (New York)
10:35-10:40	*Discussion*	
10:40-11:00	CAR-T cells in CNS lymphoma	Jeremy S. Abramson (Boston)
11:00-11:05	*Discussion*	
11:05-11:25	Mechanisms of resistance to CAR-T cell therapy	Andrei Thomas-Tikhonenko (Philadelphia)
11:25-11:30	*Discussion*	
11:30-11:50	Preparatory regimen for efficient CAR-T cell therapy	David Maloney (Seattle)
11:50-11:55	*Discussion*	
11:55-12:25	*Round table discussion*	

12:25-12:35	Early-Career Scholarship Award Ceremony	Michael Hallek (Cologne)

12:35-13:30 ***Lunch***

SESSION VI - Targeting the signaling pathways of lymphoid malignancies, monotherapies versus combination therapy
Chairs: Stephan Stilgenbauer (Ulm), Andreas Strasser (Melbourne)

13:30-13:50	Novel Btk inhibitors, acalabrutinib	Paolo Ghia (Milan)
13:50-13:55	*Discussion*	
13:55-14:15	Bcl2 inhibition in combination and monotherapy (CLL)	Stephan Stilgenbauer (Ulm)
14:15-14:20	*Discussion*	
14:20-14:40	Mcl1 inhibitors	Andreas Strasser (Melbourne)
14:40-14:45	*Discussion*	
14:45-15:05	PI3K inhibition : an update	Georg Lenz (Münster)
15:05-15:10	*Discussion*	
15:10-15:30	EZH2 inhibitors	Vincent Ribrag (Villejuif)
15:30-15:35	*Discussion*	
15:35-16:00	*Round table discussion*	
16:00-16:25	***Coffee Break***	

SESSION VII - Strategies to integrate genomics, novel agents and traditional approaches into one treatment concept
Chairs: Franck Morschhauser (Lille), Laurie Sehn (Vancouver)

16:25-16:45	CLL	Barbara Eichhorst (Cologne)
16:45-16:50	*Discussion*	
16:50-17:10	Mantle cell lymphoma	Simon Rule (Plymouth)
17:10-17:15	*Discussion*	
17:15-17:35	DLBCL	Laurie Sehn (Vancouver)
17:35-17:40	*Discussion*	
17:40-18:00	Folicular lymphoma	Franck Morschhauser (Lille)
18:00-18:05	*Discussion*	
18:05-18:25	CNS	Gerald Illerhaus (Stuttgart)
18:25-18:30	*Discussion*	
18:30-19:00	*Round table discussion*	
19:00-20:00	***Poster Walks and Get-Together Buffet Dinner***	

- Biology Poster Walk leaders: Andreas Strasser (Melbourne) & David M. Weinstock (Boston)
- Clinical Poster Walk leaders: Barbara Eichhorst (Cologne) & Franck Morschhauser (Lille)

Saturday, October 5, 2019

07:30-08:30 3 Simultaneous Meet the Expert Sessions (Clinical)

1. Diffuse large B-cell lymphoma (DLBCL) — Anas Younes (New York)
2. Mantle cell lymphoma — Simon Rule (Plymouth)
3. CLL — Paolo Ghia (Milan)

SESSION VIII - Targeted therapy of selected rare entities : an update
Chairs: Brunangelo Falini (Perugia), Michael Hallek (Cologne)

08:30-08:50	Waldenström macroglobulinemia	Christian Buske (Ulm)
08:50-08:55	*Discussion*	
08:55-09:15	Hairy cell leukaemia	Brunangelo Falini (Perugia)
09:15-09:20	*Discussion*	
09:20-09:40	KSHV-associated/AIDS-related lymphoma	Ethel Cesarman (New York)
09:40-09:45	*Discussion*	
09:45-10:05	Ph-like B-ALL	Sarah Tasian (Philadelphia)
10:05-10:10	*Discussion*	
10:10-10:40	*Round table discussion*	
10:40-11:00	***Coffee Break***	

SESSION IX - How to ensure that breakthroughs will happen now for NHL/CLL?
Innovative trial design, novel concepts of computational biology and modeling, translational studies in patients leading to discovery and functional studies. Reverse translation.
Chairs: David M. Weinstock (Boston), Anas Younes (New York)

11:00-11:20	Lymphoma xenografts: how to get back to the bench?	David M. Weinstock (Boston)
11:20-11:25	*Discussion*	
11:25-11:45	Innovative, adaptive trial design for CLL	Andrew Pettitt (Liverpool)
11:45-11:50	*Discussion*	
11:50-12:10	Imaging to guide targeted therapies	Michel Meignan (Créteil)
12:10-12:15	*Discussion*	
12:15-12:35	Precision medicine trials for lymphoma	Anas Younes (New York)
12:35-12:40	*Discussion*	
12:40-13:10	*Round table discussion*	
13:10-13:15	***Closing remarks***	Chairpersons

MEETING CLOSURE